|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
injection
single dose
mass vaccination campaigns
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:canBeTransportedAt
|
up to 40°C for 4 days
|
|
gptkbp:contains
|
polysaccharide-protein conjugate
|
|
gptkbp:costPerDose
|
less than US$0.50
|
|
gptkbp:developedBy
|
gptkb:PATH
gptkb:World_Health_Organization
gptkb:Serum_Institute_of_India
|
|
gptkbp:fundedBy
|
gptkb:Bill_&_Melinda_Gates_Foundation
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MenAfriVac vaccine
|
|
gptkbp:includedIn
|
Expanded Programme on Immunization (EPI) in Africa
routine immunization schedules in Africa
|
|
gptkbp:indication
|
individuals aged 1 to 29 years
|
|
gptkbp:introducedIn
|
gptkb:Burkina_Faso
2010
|
|
gptkbp:notRecommendedFor
|
children under 1 year
adults over 29 years
|
|
gptkbp:prevention
|
epidemic meningitis
meningococcal disease
|
|
gptkbp:reduces
|
incidence of meningitis A
|
|
gptkbp:sideEffect
|
headache
mild fever
pain at injection site
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:Neisseria_meningitidis_serogroup_A
|
|
gptkbp:type
|
vaccine
|
|
gptkbp:usedFor
|
prevention of meningitis
|
|
gptkbp:usedIn
|
gptkb:African_meningitis_belt
|
|
gptkbp:WHOPrequalified
|
yes
|
|
gptkbp:bfsParent
|
gptkb:meningitis_A
|
|
gptkbp:bfsLayer
|
7
|